

CURRICULUM VITAE

M. PETER LANCE

OFFICE ADDRESS

Arizona Cancer Center
1515 N. Campbell Avenue, P.O. Box 245024
Tucson, AZ 85724-5024
Phone: (520) 626-4492
Fax: (520) 626-5348
plance@uacc.arizona.edu

EDUCATION

M.B., B.Chir., University of Cambridge	1972
M.A. (Medical Sciences), University of Cambridge	1972
B.A. (Medical Sciences), University of Cambridge	1968

PROFESSIONAL QUALIFICATIONS, LICENSES AND BOARD CERTIFICATION

Provisional Registration General Medical Council of Great Britain	1972
Full Registration General Medical Council No. 1518812	1973
Member, Royal College of Physicians of London (M.R.C.P.) By Examination	1975
Visa Qualifying Examination No. 359-469-4 Basic Sciences and Clinical Sciences	1982
ECFMG English Test No. 359-469-4	1983
FLEX NO. 470511006	1983
Rhode Island State License No. 6277	1983
American Board of Internal Medicine Diplomate in Internal Medicine No. 095277	1983
Accredited by Specialist Advisory Committees of Joint Committee on Higher Medical Training (UK) in General (Internal) Medicine and Gastroenterology	1984
American Board of Internal Medicine Subspecialty Diplomate in Gastroenterology No. 095277	1985
New York State License No. 173022	1987
Fellow, Royal College of Physicians of London (F.R.C.P.) By Election	1993
Doctor of Medicine (M.D.) Conferred by the Board of Regents New York State Education Department	2001
Arizona State License No. 29711	2001

EMPLOYMENT HISTORY

Kingston-upon-Hull Hospitals, England House Officer and Senior House Officer (Medical Residency equivalent)	1972 – 1974
University of Birmingham Hospitals, England Registrar in General Internal Medicine and Gastroenterology (PGY3/First Year Fellow equivalent)	1974 – 1976
University of London, Westminster Medical School Research Graduate	1977 – 1978
University of London, Westminster Hospital and Medical School Senior Medical Registrar (Gastroenterology) (Second and Third Year Fellow equivalent)	1978 – 1981
University of California San Francisco Postdoctoral Research Fellow	1981 – 1982
Brown University Medical School Special Fellow in Gastrointestinal Oncology	1982 – 1983
Brown University Medical School Assistant Professor of Medicine	1983 – 1987
Roger Williams General Hospital, Providence, RI Director, Division of Gastroenterology and Attending Physician	1983 – 1987
Veterans Administration Medical Center Providence, RI Consultant Physician	1984 – 1987
Rhode Island Hospital, Providence, RI Consultant Physician	1986 – 1987
State University of New York at Buffalo Assistant Professor of Medicine	1987 – 1992
State University of New York at Buffalo Associate Professor of Medicine With Tenure	1992 – 2000
Veterans Administration Medical Center Buffalo, NY Attending Physician	1987 – 2001
Veterans Administration Medical Center Buffalo, NY Director, GI Section	1987 – 1994
Buffalo General Hospital, Buffalo, NY Associate Physician, Department of Medicine Academic Staff	1988 – 1994
Erie County Medical Center, Buffalo, NY Attending Physician, Department of Internal Medicine	1989 – 2001
Roswell Park Cancer Institute, Buffalo, NY Consultant in Gastroenterology Department of Medicine	1990 – 2000
State University of New York at Buffalo Department of Medicine Chief, Division of Gastroenterology	1994 – 2001
State University of New York at Buffalo Program Director, Gastroenterology Fellowship Training	1994 – 2001

Buffalo General Hospital, Buffalo, NY Chief, Division of Gastroenterology and Attending Physician	1994 – 1998
Tri-County Hospital, Gowanda, NY Consulting Staff	1994 – 1998
Millard Fillmore Hospital, Buffalo, NY Consultant, Academic Staff	1997 – 2001
KALEIDA Health System, Buffalo, NY Head, Division of Gastroenterology	1998 – 2001
State University of New York Associate Professor of Physiology	1999 – 2001
Roswell Park Cancer Institute, Buffalo, NY Staff Physician	2000 – 2001
State University of New York at Buffalo Professor of Medicine with Tenure	2000 – 2001
University of Arizona Professor of Medicine (with Tenure)	2001 –
University of Arizona Health Sciences Center Attending Physician	2001 –
University Physicians, Inc. Tucson, AZ	2001 –
NCI-Designated Cancer Center – Arizona Cancer Center Comprehensive Member	2002 –
Arizona Cancer Center Member, Cancer Biology Graduate Interdisciplinary Program	2002 –
University of Arizona Professor of Molecular and Cellular Biology	2002 –
University of Arizona Professor of Public Health	2003 –
Arizona Cancer Center Director, Cancer Prevention and Control Program	2005 – 2011
University of Arizona Clinical Research Unit (formerly General Clinical Research Center) Medical Director	2008 –
Arizona Cancer Center Chief Cancer Control Officer	2008 – 2011
Arizona Cancer Center Chief Cancer Prevention and Control Officer	2011 –
University of Arizona Cancer Center (official name change) Interim Deputy Director – Phoenix	2013 –

AWARDS AND HONORS

Runcorn Traveling Fellowship	1980
SW Thames Regional Hospital Board	
Peel Fellowship, Peel Medical Research Trust of Great Britain	1981
White Coat Award (the faculty member selected each year by the Internal Medicine Residents for excellence in teaching) Department of Medicine, State University of New York at Buffalo	1998

The University of Arizona Cancer Center Sydney E. Salmon Award 2012
Distinguished Senior Investigator

PROFESSIONAL MEMBERSHIPS AND ACTIVITIES

National Committees

1987 – 1988	Member, Abstract Selection Committee American Gastroenterological Association Molecular and Cell Biology Section (Chairman, 1988)
1991 – 1992	Member, Program Evaluation Committee American Gastroenterological Association
1992 – 1995	Chairman, Program Evaluation Committee American Gastroenterological Association
1991 – 1992	Member, Abstract Selection Committee American Gastroenterological Association Gastrointestinal Oncology Section
1992 – 1993	Chairman, Abstract Selection Committee, Gastrointestinal Oncology Section, American Gastroenterological Association
1998 –	Member, Abstract Selection Committees American Gastroenterological Association
1999 – 2001	Director, American Gastroenterological Association Annual Postgraduate Course, DDW 2001(Atlanta, GA)

Reviewing of Grants

1991	Ad hoc Reviewer, Career Development Program Applications, Veterans Administration
1992 – 1994	Invited Reviewer, Epidemiology and Disease Control 2 Study Section, National Institutes of Health
1996	Invited Reviewer, United States-Israel Binational Science Foundation
1999 – 2001	Ad hoc Reviewer, Merit Review applications Department of Veterans Affairs Medical Research Service
2002 –	Ad hoc Reviewer, National Cancer Institute
2004 – 2006	Chair, NIH Review Panel, PAR 04-036 Colorectal Cancer Screening in Primary Care Practice
March 2005	Ad hoc Reviewer, Early Detection Research Network, National Cancer Institute
June 2007	Chair, NIH Special Emphasis Panel (NHLBI RR-07-09) Management Support Center for the CTSA Awards
February 2009	NCI Mouse Models of Human Cancer Consortium Special Emphasis Panel I

Editorship and Reviewing of Articles

2002 – 2005	Associate Editor, CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
2005 – 2008	Senior Editor, CANCER EPIDEMIOLOGY BIOMARKERS &

June 2013
Lance

2006 – PREVENTION
Editorial Board Member, JOURNAL OF CLINICAL
ONCOLOGY

Reviewing of Articles

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
AMERICAN JOURNAL OF GASTROENTEROLOGY
BIOCHIMI BIOPHYSICA ACTA
CANCER
CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION
CANCER PREVENTION RESEARCH
CANCER RESEARCH
CLINICAL CANCER RESEARCH
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
DIGESTIVE DISEASES AND SCIENCES
GASTROENTEROLOGY
GUT
AMERICAN JOURNAL OF PHYSIOLOGY CELL PHYSIOLOGY
JOURNAL OF CARCINOGENESIS
JOURNAL OF CLINICAL INVESTIGATION
JOURNAL OF CLINICAL ONCOLOGY
JOURNAL OF LIPID RESEARCH
NEW ENGLAND JOURNAL OF MEDICINE
ONCOGENE
PLoS COMPUTATIONAL BIOLOGY

Membership in Societies

American Association for Cancer Research
American Association for the Advancement of Science
American Association for the Study of Liver Diseases
American Cancer Society
American College of Gastroenterology (Fellow)
American Federation for Clinical Research
American Gastroenterological Association
American Society for Biochemistry and Molecular Biology
American Society of Clinical Oncology
British Society of Gastroenterology
Gastrointestinal Pathology Society
Medical Research Society of Great Britain
Royal College of Physicians of London (Fellow, by election)

SELECTED EDUCATIONAL ACTIVITIES (Since 1992)

National

American Gastroenterological Association

Member of Faculty and Lecturer, Annual Board Review Course;
Chicago

September 1993

Member of Faculty and Lecturer, Annual Postgraduate Course; May 1996
San Francisco

Course Director for AGA Spring Postgraduate Course; May 2001
Atlanta

University of Arizona Courses Taught (Since 2001)

Cancer Prevention and Control Seminar Series (EPI 696B)
Cancer Biology Seminar Series (CBIO 596H)
Cancer Prevention Epidemiology MPH and MS Epidemiology Course (EPI 615A)
Basic Principles of Epidemiology (573A)

Research Supervision

1. GI Fellow: S. Shah, M.D., NIH Training Grant (Milton M. Weiser, M.D.) Trainee, Research Fellow in my laboratory (7/1/89 – 12/31/90).
2. Thesis Committee, member: Candidate, S-P Tzung, M.D., Graduate Student in Department of Experimental Therapeutics, State University of New York at Buffalo, Roswell Park Memorial Institute Division. Graduated Ph.D., May 1991.
3. GI Fellow: J. Piscatelli, M.D., NIH Training Grant (Milton M. Weiser, M.D.) Trainee, Research Fellow in my laboratory (7/1/91 – 12/31/92).
4. Masters Committee, Department of Nutrition (1992). Student: Denise Feeley.
5. Masters Committee, Department of Nutrition (1993). Student: Nancy Garrison.
6. Postdoctoral Research Fellow in Cancer Epidemiology: Ming Li, M.D., Ph.D., on NIH Training Grant (Co-Investigator, M. Peter Lance, M.D.). Dr. Li conducted this Research Fellowship in my laboratory (7/1/93 – 6/30/95).
7. Masters Committee, Department of Social and Preventive Medicine (1994). Student: Marcia Gruber.
8. GI Fellow: R. Vemulapalli, M.D.: Research Fellow in my laboratory (1/1/94 – 6/30/95).
9. GI Fellow: A. Ullah, M.D.: Research Fellow in my laboratory (1/1/95 – 6/30/96)
10. GI Fellow: U. Srivatana, M.D.: Research Fellow in my laboratory (1/1/97 – 12/31/97)
11. GI Fellow: A. Marhaba, M.D.: Research Fellow in my laboratory (2/1/98 – 31/1/99)
12. GI Fellow: H. Gagneja, M.D.: Research Fellow in my laboratory (1/1/99 – 31/12/99)
13. Doctoral Student (Physiology): H. Jones, M.S. (9/1/98 – 12/31/2001). Awarded her Ph.D. in Physiology, January 2002.
14. Doctoral Student (Molecular & Cellular Biology) R. El Bejjani. (Pre-doctoral supervisor, 2002 – 2007)
15. M.D., Ph.D. Student: N. Rial. (Pre-doctoral supervisor, 2005 – 2007). Awarded his PhD in 2007 and MD in 2008.

SELECTED VISITING PROFESSORSHIPS AND OTHER EXTERNAL ENGAGEMENTS

1. American Gastroenterological Association: DDW Colorectal Cancer Screening Symposium, San Francisco, May 1992.
2. University of Michigan, Ann Arbor; November 1992.
3. Liverpool University, Liverpool, U.K.; March 1993.
4. Hull University, Hull, U.K.; March 1993.
5. American Gastroenterological Association: Lecturer, Fall Postgraduate Course, Chicago, September 1993.
6. Albany Medical College, Albany, New York; December 1993.
7. Brown University, Providence, RI; November 1995.
8. American Gastroenterological Association: Lecturer, Spring Postgraduate Course, San Francisco, May 1996.
9. University of Newcastle, Newcastle, U.K.: November 1996. Society of Gastroenterology Nurses and

- Associates: Invited speaker, Annual Meeting, Orlando, FL, May 1997.
10. American Gastroenterological Association: Meet-the-Professor Lunch, Annual Meeting, Washington, May 1997.
 11. American College of Physicians New York State Chapter Annual Scientific Meeting (October 1997): Colorectal cancer screening.
 12. Brown University, Providence, RI: GI Research Seminar, November 1998.
 13. Tufts University, Faulkner Hospital, Boston, MA: Research Seminar, March 1999.
 14. Tufts University, St. Elizabeth's Hospital, Boston, MA: Medical Grand Rounds, March 1999.
 15. Royal College of Physicians of London, England: Invited speaker, symposium on colorectal cancer, June 1999.
 16. Guthrie Clinic, Sayre, PA: Medical Grand Rounds, June 1999.
 17. Marshall University, WVA: Medical Grand Rounds, October 1999.
 18. University of Arizona Cancer Center, Tucson, AZ: Cancer Biology Seminar Series, October 1999.
 19. University of California, San Diego: Visiting Professor, February 2000.
 20. University of California, San Diego: Guest Faculty, Department of Medicine Annual Topics in Internal Medicine Course, February 2000.
 21. University of Arkansas, Guest Faculty for Annual Rasco Colorectal Cancer Symposium, September 2000
 22. Dartmouth Polyp Group (NCI): Invited Speaker, Annual Investigators Meeting, Denver, CO, September 2002.
 23. Phoenix Annual Internal Medicine Update, Invited Speaker, November 2002.
 24. Vanderbilt University: Visiting Professor, Invited Speaker, January 2003.
 25. 7th Seoul International Digestive Diseases Symposium (SIDD Symposium), Invited Speaker, November 2003.
 26. Annual Meeting, Korean Association for the Study of Intestinal Disease, Invited Speaker, November 2003.
 27. Rasco Symposium, University of Arkansas for Medical Sciences, Little Rock, AR., March, 2004.
 28. Annual Oncology Symposium: Screening and Prevention, Swedish Medical Center, Seattle, WA, May 2005.
 29. Mt. Sinai Medical Center, New York, NY, Visiting Professor, September 2006.
 30. University of California Irvine, Invited Speaker, June 2007.
 31. American Association for Cancer Research Cancer Disparities Conference, Atlanta GA, Invited Speaker, November 2007.
 32. American Society for Preventive Oncology, Invited Speaker, March 2008.
 33. Imperial College, London, UK, Visiting Professor, April 2010
 34. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, February 2011
 35. University of Indiana Cancer Center, Indianapolis, IN, February 2011

COMMITTEE MEMBERSHIPS (since 2001)

State /Regional

Dialogue for Action: Capacity Building for Colorectal Screening in the Southwest Co-Chair, Planning Committee	2002
Arizona State Comprehensive Cancer Control Coalition, Member	2002 –
Arizona State Comprehensive Cancer Control Steering Committee, Member	2005 – 2010
Arizona Department of Health Services Medical Director, State Colon Cancer Screening Program	2007 –

June 2013
Lance

University

Member, University of Arizona Committee on Promotion and Tenure 2011 – 2012
Chair, University of Arizona Committee on Promotion and Tenure 2012 – 2013

College of Medicine

General Clinical Research Center Advisory Committee 2002 – 2004

Chair, Search Committee for Head, Department of Pathology 2006 – 2008

Member, Center Directors Council 2007 –

Arizona Cancer Center

Arizona Cancer Center Cabinet, Member 2002 – 2004

Executive Committee, Member 2004

Director's Committee, Member 2005 –

Cancer Prevention and Control Training (R25) Grant Advisory Committee 2002 –

Translational Research Committee, Member 2005 – 2008

Native American Cancer Research Partnership (U54 Grant) Advisory Board 2005 –

Senior Leadership (Director's Executive Committee) in capacity as Chief Cancer Prevention and Control Officer 2008 –

GRANT SUPPORT

Active

Joint Principal Investigator 08/01/11-06/30/14 NIH/NCI: 1R01 CA151708-01A1 Selenium Colorectal Cancer Chemoprevention Trials
Annual Direct Costs: \$1,300,326

Co-Investigator Project 1 6/1/02-3/31/13 NIH/NCI: 1 P50 CA 95060-01 SPORE in GI Cancer: Project 1
Principal Investigator: Eugene Gerner, Ph.D, Arizona Cancer Center
Annual Direct Costs for Project 1: \$243,898

Senior Leader 7/1/09 – 6/30/14 NIH/NCI: P30 CA023074 Arizona Cancer Center Support Grant
Principal Investigator: David S. Alberts, M.D., Arizona Cancer Center
Annual Direct Costs for Dr. Lance: \$33,340

Principal Investigator 10/01/07-12/31/12 ADHS: HA861132 Medical Director of Colorectal Cancer Screening Program
Annual Direct Costs for Dr. Lance \$36,364

Joint Principal Investigator 08/01/12 – 7/31/14 University of Arizona Cancer Center Support Grant Pilot Project: High Fat Diet and Epigenetics of Sporadic Colon Cancer
Annual Direct Costs: \$30,000

Completed (since 2002)

Principal Investigator University of Arizona NIH/NCI: 1U01 CA74799 Colon Cancer Family Registry
Principal Investigator: Robert W. Haile, Ph.D., University of Southern

Subcontract 8/1/02 – 8/31/12	California Annual Direct Costs for University of Arizona Subcontract \$67,545
Principal Investigator 9/04/07 – 8/31/12	NIH/NCI: 1R01 CA124862 Colorectal Neoplasia in SELECT Participants Annual Direct Costs: \$441,167
Principal Investigator 8/01/05 – 7/31/11 (No cost extension 8/01/10 – 7/31/11)	NIH/NCI: 2P02 CA41108 Colon Cancer Prevention Program Project: Overall Principal Investigator: M. Peter Lance, M.D. Annual Direct Costs: \$3,110,949
Leader – Project I 8/01/05-7/31/11 (No cost extension 8/01/10 – 7/31/11)	NIH/NCI: 2P02 CA41108 Colon Cancer Prevention Program Project Project I: Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence Annual Direct Costs: \$1,227,797
Principal Investigator University of Arizona Subcontract 6/1/2001 – 8/31/05	NIH/NCI: 1 UO1 CA 89389 Colorectal Cancer Screening: Fecal Blood vs DNA Principal Investigator: David A. Ahlquist, M.D., Mayo Clinic Dr. Lance assembled a University of Arizona clinical center for the proposal Annual University of Arizona Subcontract: \$189,993
Co-Director 4/01/04-6/01/05	ADHS: “A Comprehensive Plan to Insure Capacity for Screening and Early Detection of Colorectal Cancer in Arizona” Annual Direct Costs: \$231,050
Principal Investigator 07/01/06 – 12/31/06	ADHS: “Navajo Reservation Gastrointestinal Cancer Prevention Program” Annual Direct Costs: \$9,727
Co-Investigator 9/1/03 – 8/31/09	NIH/NCI: Promoting Colon Cancer Screening in High Risk Families Principal Investigator: Dennis J. Ahnen, M.D., University of Colorado Annual Direct Costs: \$2,334

PUBLICATIONS

I. Peer-Reviewed Articles

1. **Lance P**, Bevan PG, Hoult JG, Paton A. Liver biopsy in "difficult" jaundice. Br Med J 1977; 2:236.
2. Lewis KO, Nicholson G, **Lance P**, Paton A. Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs. J Clin Pathol 1977; 30:1040-1043.
3. **Lance P**, Gazzard BG. Controlled trial of cimetidine for symptomatic treatment of duodenal ulcers. Br Med J 1983; 286:937-938.
4. **Lance P**, Gazzard BG. Ulcerative enteritis and liver disease in a patient with coeliac disease. Gut 1983; 24:433-437.
5. Boland CR, **Lance P**, Levin B, Riddell RH, Kim YS. Abnormal goblet cell glycoconjugates in rectal biopsies associated with an increased risk of neoplasia in patients with ulcerative colitis: early results of a prospective study. Gut 1984; 25:1364-1371.
6. Lev R, **Lance P**, Camara P. Histochemical and morphological studies of mucosa bordering rectosigmoid carcinomas: comparisons with normal, diseased, and malignant colonic epithelium. Hum Pathol 1985; 16:151-161.
7. **Lance P**, Gibson-Glubb S, Gazzard JA, Gazzard BG. Chronic dyspepsia pain in general practice - its causes and diagnosis. Postgrad Med J 1985; 61:411-413.
8. **Lance P**, Wastell C. Schiller KFR. A controlled trial of cimetidine for the treatment of non-ulcer

- dyspepsia. *J Clin Gastroenterol* 1986; 8:414-418.
9. Lev R, Lebenthal E, Rossi T, **Lance P**. Histochemical and morphological analysis of colonic epithelium from children with Gardner's syndrome and adults bearing adenomatous polyps. *J Pediatric Gastroenterol Nutr* 1987; 6:414-425.
 10. Masterson-Allen S, Mor V, **Lance P**. Physician screening practices and colorectal cancer screening prevalence among the Rhode Island population. *Rhode Island Medical Journal* 1987; 70:217-221.
 11. **Lance P**, Lau K, Lau JTY. Isolation and characterization of a partial cDNA for a human sialyltransferase. *Biochem Biophys Res Commun* 1989; 164:225-232.
 12. Tzung S-P, Gaines KC, **Lance P**, Ehrke MJ, Cohen SA. Suppression of hepatic lymphokine-activated-killer cell induction by murine Kupffer cells and hepatocytes. *Hepatology* 1990; 12:644-652.
 13. **Lance P**, Lev R. Colonic oligosaccharide structures deduced from lectin-binding studies before and after desialylation.¹ *Hum Pathol* 1991; 22:307-312.
 14. The Veterans Affairs Cooperative Variceal Sclerotherapy Group (**Lance P**, Participating Investigator). Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease - A randomized, single-blind, multicenter clinical trial. *N Engl J Med* 1991; 324:1779-1784.
 15. Fay DE, Poplasky M, Gruber M, **Lance P**. Long-term enteral feeding: A retrospective comparison of delivery via percutaneous endoscopic gastrostomy and nasoenteric tubes. *Am J Gastroenterol* 1991;86:1604-1609.
 16. Gruber M, Fay D, Pudhorodsky T, **Lance P**. Palatability of colonic lavage solution is improved by the addition of artificially sweetened flavored drink mixes. *Gastroenterology Nursing* 1991; 14:135-137.
 17. Shah S, **Lance P**, Smith TJ, Berenson CS, Cohen SA, Horvath PJ, Lau JTY, Baumann H. *n*-Butyrate reduces the expression of β -galactoside α 2,6-sialyltransferase in Hep G2 cells. *J Biol Chem* 1992; 267:10652-10658.
 18. Tzung S-P, Mahl TC, **Lance P**, Andersen V, Cohen SA. Interferon- α prevents endotoxin-induced mortality in mice. *Eur J Immunol* 1992; 22:3097-3101.
 19. **Lance P**. Fecal occult blood tests. What's new? (editorial). *Gastroenterology* 1993; 104:1852-1855.
 20. The Veterans Affairs Cooperative Sclerotherapy Group (**Lance P**, Participating Investigator). Sclerotherapy for male alcoholic cirrhotics who have bled from esophageal varices: Results of a randomized, multicenter clinical trial. *Hepatology* 1994; 20:618-625.
 21. Vemulapalli R, **Lance P**. Cancer surveillance in ulcerative colitis: More of the same or progress? (editorial). *Gastroenterology* 1994; 107:1196-1199.
 22. Piscatelli JJ, Cohen SA, Berenson CS, **Lance P**. Determinants of differential liver-colonizing potential of variants of a murine colon cancer cell line. *Clin Exp Metastasis* 1995; 13:141-150.
 23. Berenson CS, Patterson MA, Miqdadi J, **Lance P**. *n*-Butyrate mediation of ganglioside expression of human and murine cancer cells demonstrates relative cell specificity. *Clin Sci* 1995; 88:491-499.
 24. Li M, Andersen V, **Lance P**. Expression and regulation of glycosyltransferases for N-glycosyl oligosaccharides in fresh human surgical and murine tissues and cultured cell lines. *Clin Sci* 1995; 89:397-404.
 25. Gruber M, Marshall JR, Zielezny M, **Lance P**. A case-control study to examine the influence of maternal perinatal behaviors on the incidence of Crohn's disease. *Gastroenterology Nursing* 1996; 19:53-59.
 26. Smith TJ, Piscatelli JJ, Andersen V, Wang H-S, **Lance P**. *n*-Butyrate induces plasminogen activator inhibitor type-I in Hep G2 cells in culture. *Hepatology* 1996; 23:866-871.
 27. The Polyp Prevention Trial Study Group (**Lance P**, Principal Investigator, Buffalo Clinical Center). The Polyp Prevention Trial I. Rationale, design, recruitment, and baseline participant characteristics. *Cancer Epidemiol Biomarkers Prev* 1996; 5:375-383.
 28. The Polyp Prevention Trial Study Group (**Lance P**, Principal Investigator, Buffalo Clinical Center). The Polyp Prevention Trial II. Dietary intervention program and participant baseline dietary characteristics. *Cancer Epidemiol Biomarkers Prev* 1996; 5:385-392.
 29. Marshall JR, Fay DE, **Lance P**. Flexible sigmoidoscopic screening for colorectal cancer: Relative costs of alternative strategies.² *Gastroenterology* 1996; 111:1411-1417.
 30. The Polyp Prevention Trial Study Group (**Lance P**, Principal Investigator, Buffalo Clinical Center). Indexes of food and nutrient intakes as predictors of serum concentrations of nutrients: the problem of inadequate discriminant validity. *Am J Clin Nutr* 1997 ;65: 1269S-1274S.

¹ An editorial on this paper appeared in the same issue of the journal.

² An editorial on this paper appeared in the same issue of the journal.

31. The Veterans Affairs Cooperative Sclerotherapy Group (**Lance P**, Participating Investigator). Sclerotherapy for actively bleeding esophageal varices in male alcoholics with cirrhosis. *Gastrointest Endosc* 1997;46: 1-7.
32. Li M, Vemulapalli R, Ullah A, Izu L, Duffey ME, **Lance P**. Down-regulation of a human colonic sialyltransferase by a secondary bile acid and a phorbol ester.³ *Am J Physiol Gastrointest Liver Physiol* 1998; 274: G599-G606.
33. Schoen RE, Corle D, Cranston L, Weissfeld JL, **Lance P**, Burt R, Iber F, Shike M, Kikendall JW, Hasson M, Lewin KJ, Appleman HD, Paskett E, Selby JV, Lanza E, Schatzkin A for the PPT. Is colonoscopy needed for the non-advanced adenoma found on sigmoidoscopy? Relationships between distal and proximal adenomas in the Polyp Prevention Trial.⁴ *Gastroenterology* 1998; 115: 533-541.
34. Kim EC, Zhu Y, Andersen V, Sciaky D, Cao HJ, Smith TJ, Lance P. Cytokine-mediated PGE₂ expression in human colonic fibroblasts. *Am J Physiol Cell Physiol* 1998; 275: C988-C994.
35. Schatzkin A, Lanza E, Corle D, Freedman L, **Lance P**, Iber F, Caan B, Shike M, Weissfeld J, Burt R, Cooper R, Kikendall W, Cahill J. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. *N Engl J Med* 2000; 342: 1149-1155.
36. Zhu Y, Srivatanana U, Ullah A, Gagneja H, Marhaba A, Berenson CS, **Lance P**. Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. *Biochim Biophys Acta* 2001; 1536: 148-160.
37. Lanza E, Schatzkin A, Daston C, Corle D, Freedman L, Ballard-Barbash R, Caan B, **Lance P**, Marshall J, Iber F, Shike M, Weissfeld J, Slattery M, Paskett E, Mateski D, Albert P. Implementation of a 4-y, high fiber, high-fruit-and-vegetable, low-fat dietary intervention: results of dietary changes in the Polyp Prevention Trial. *Am J Clin Nutr* 2001; 74: 387-401. PMID: 11522565
38. Woodson K, Lanza E, Tangrea JA, Albert PS, Slattery M, Pinsky J, Caan B, Cooper R, Iber F, Kikendall W, **Lance P**, Shike M, Weissfeld J, Schatzkin A. Hormone replacement therapy and colorectal adenoma recurrence among women participants of the Polyp Prevention Trial. *J Natl Cancer Inst* 2001; 93: 1799-1805.
39. Colbert LH, Lanza E, Ballard-Barbash R, Slattery ML, Tangrea JA, Caan B, Paskett ED, Iber F, Kikendall W, **Lance P**, Shike M, Schoen RE, Daston C, Schatzkin A. Adenomatous polyp recurrence and physical activity in the Polyp Prevention Trial (United States). *Cancer Causes Control* 2002; 13: 445-453.
40. Zhu Y, Hua P, Fariq S, Waffner E, Duffey ME, **Lance P**. Ca²⁺- and PKC-dependent stimulation of PGE₂ synthesis by deoxycholic acid in human colonic fibroblasts. *Am J Physiol Gastrointest Liver Physiol* 2002; 283: G503-G510.
41. Zhu Y, Hua P, **Lance P**. Cyclooxygenase-2 expression and prostanoid biogenesis reflect clinical phenotype in human colorectal fibroblast strains. *Cancer Res* 2003;63:522-526.
42. Tangrea JA, Albert PS, Lanza E, Woodson K, Corle D, Hasson M, Burt R, Caan B, Paskett E, Iber F, Kikendall W, **Lance P**, Shike M, Weissfeld J, Schatzkin A. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). *Cancer Causes Control* 2003; 14: 403-411.
43. Mathew A, Sinha R, Burt R, Caan B, Paskett E, Iber F, Kikendall W, **Lance P**, Shike M, Weissfeld J, Schatzkin A, Lanza E, and the Polyp Prevention Study Group. Meat intake and the recurrence of colorectal adenomas. *Eur J Cancer Prev* 2004; 13: 159-164.
44. Alberts DS, Martinez ME, Green S, Roe D, Einspahr J, Bhattacharya AB, Guillen J, Clouser M, Hess LM, Krutzsch M, Batta AK, Salen G, **Lance P**. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. *J Natl Cancer Inst* 2005; 97: 846-853.
45. Alberts D, Potter J, Martinez ME, Hess L, Stopeck A, **Lance P**. What happened to the coxibs on the way to the Cardiologist?. *Cancer Epidemiol Biomarker Prev* 2005; 14: 555-556.
46. Pabby A, Schoen R, Weissfeld J, Burt R, Kikendall JW, **Lance P**, Shike M, Lanza E, Schatzkin A. Analysis of Colorectal Cancer Occurrence During Surveillance Colonoscopy in the Dietary Polyp Prevention Trial. *Gastrointest Endosc* 2005; 61: 385-391.
47. Gerner EW, Ignatenko NA, **Lance P**, Hurley LH. A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli (APC) tumor suppressor gene. *Ann NY Acad Sci* 2005; 1059: 97-105.

³ This paper appeared in the category of "Expedited Article".

⁴ An editorial on this paper appeared in the same issue of the journal.

48. Ranger Moore J, Frank D, **Lance P**, Alberts D, Yozwiak M, Bartels HG, Bartels PH. Karyometry in rectal mucosa of patients with previous colorectal adenomas. *Anal Quant Cyto Histol* 2005; 27: 134-142.
49. Paskett E, Reeves K, Pineau B, Albert P, Caan B, Hasson M, Iber F, Kikendall JW, **Lance P**, Shike M, Slattery ML, Weissfeld, Kahle L, Schatzkin A, Lanza E. The association between cigarette smoking and colorectal polyp recurrence. *Cancer Causes Control* 2005; 16: 1021-1033.
50. Nelson MA, Goulet A-C, Jacobs ET, **Lance P**. Studies into the anticancer effects of selenomethionine against human colon cancer. *Ann NY Acad Sci* 2005; 1059: 26-32.
51. Lanza E, Hartman TJ, Albert PS, Shields R, Slattery M, Caan B, Paskett E, Iber F, Kirkendall JW, **Lance P**, Daston C, Schatzkin A. High dry bean intake and reduced risk of advanced colorectal adenoma recurrence among participants in the polyp prevention trial. *J Nutr* 2006; 136: 1896-1903. PMC1713264
52. **Lance P**. The cancer genome and diagnostic blood tests. *Cancer Epidemiol Biomarker Prev* 2006; 15: 2017-2018
53. Jacobs ET, Martinez ME, Alberts DS, Jiang R, **Lance P**, Lowe KA, Thompson PA. Association between body size and colorectal adenoma recurrence. *Clin Gastroenterol Hepatol* 2007; 5: 982-990. PMC2727215
54. Gerner EW, Meyskens FL Jr, Goldschmid S, **Lance P**, Pelot D. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. *Amino Acids* 2007; 33:189-195. Martinez M, Jacobs E, Ashbeck E, Sinha R, **Lance P**, Alberts D, Thompson P. Meat intake, preparation methods, mutagens, and colorectal adenoma recurrence. *Carcinogenesis* 2007; 28: 2019-2027.
55. Lanza E, Yu B, Murphy G, Albert PS, Caan B, Marshall JR, **Lance P**, Paskett ED, Wiessfeld J, Slattery M, Burt R, Iber F, Shike M, Kikendall JW, Brewer B, Schatzkin A. The polyp prevention trial continued follow-up study: no effect of a low fat, high fiber, high fruit and vegetable diet on adenoma recurrence eight years after randomization. *Cancer Epidemiol Biomarker Prev* 2007; 16:1745-1752.
56. Alberts DS, Einspahr J, Krouse RS, Prasad A, Ranger-Moore J, Hamilton P, Ismail A, **Lance P**, Goldschmid S, Hess LM, Yozwiak M, Bartels HC, Bartels PH. Karyometry of the colonic mucosa. *Cancer Epidemiol Biomarkers Prev* 2007; 16: 2704-2716.
57. **Lance P**. Chemoprevention for colorectal cancer: Some progress but a long way to go. *Gastroenterology* 2008; 134:341-353.
58. Laiyemo AO, Murphy G, Sansbury L, Wang Z, Albert PS, Schatzkin A, Marcus PM, Caan B, Marshall JR, **Lance P**, Paskett ED, Weissfeld J, Slattery ML, Burt R, Iber F, Shike M, Kikendall JW, Lanza E. Postpolypectomy colonoscopy surveillance guidelines: Predictive accuracy for advanced adenoma at 4 years. *Ann Intern Med* 2008; 148:419-426.
59. Jacobs ET, Martinez ME, Alberts DS, Ashbeck EL, Gapstur SM, **Lance P**, Thompson PA. Plasma insulin-like growth factor 1 is inversely associated with colorectal adenoma recurrence: a novel hypothesis. *Cancer Epidemiol Biomarkers Prev* 2008; 17:300-305.
60. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, **Lance P**, Obara S, Chew EY, Kim J, Arndt G, Hawk E. Cardiovascular risk of celecoxib in six randomized placebo-controlled trials: the Cross Trial Safety Analysis. *Circulation* 2008;117:2104-2113. PMC2965408
61. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa S, Carpenter P, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Alpers CG, Ahnen DJ, Turgeon DK, Goldschmid S, **Lance P**, Hagedorn C, Gillen DL, Gerner EW. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. *Cancer Prev Res (Phila)* 2008;1:32-38. PMC2562024
62. **Lance P**, Hamilton SR. Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention. *Cancer Prev Res (Phila)* 2008;1:4-8.
63. **Lance P**. Colorectal cancer screening: confusion reigns. *Cancer Epidemiol Biomarkers Prev* 2008;17:32-38.
64. Bobe G, Sansbury LB, Albert PS, Cross AJ, Kahle L, Ashby J, Slattery ML, Caan B, Paskett E, Iber F, Kikendall JW, **Lance P**, Daston C, Marshall JR, Schatzkin A, Lanza E. Dietary flavonoids and colorectal adenoma recurrence in the Polyp Prevention Trial. *Cancer Epidemiol Biomarkers Prev* 2008;17:1344-1353. PMC2517243
65. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, **Lance P**, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL. Stool DNA and occult

- blood testing for screen-detection of colorectal neoplasia: a prospective multi-center study. *Ann Intern Med* 2008;149:441-450.
66. Joshi AD, Corral R, Siegmund KD, Conti DV, Haile RW, Le Marchand L, Ahnen DJ, Sandler RS, **Lance P**, Stern MC. Red meat and poultry intake, polymorphisms in the nucleotide excision repair and mismatch repair pathways, and colorectal cancer risk. *Carcinogenesis* 2009;30(3):472-479. PMC2722151
 67. Rial NS, Lazennec G, Prasad AR, Krouse RS, **Lance P**, Gerner EW. Regulation of deoxycholate induction of CXCL8 by the *Adenomatous Polyposis Coli* gene in colorectal cancer. *Int J Cancer* 2009;124(10):2270-2280. PMC2669776
 68. Jacobs ET, Ahnen DJ, Ashbeck EL, Baron JA, Greenberg ER, **Lance P**, Lieberman DA, McKeown-Eyssen G, Schatzkin A, Thompson PA, Martinez ME. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. *Am J Epidemiol* 2009;169:657-666. PMC2727215
 69. Zou H, Taylor WR, Harrington JJ, Hussain FT, Cao X, Loprinzi CL, Levine TR, Rex DK, Ahnen D, Knigge KL, **Lance P**, Jiang X, Smith DI, Ahlquist DA. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. *Gastroenterology* 2009;136:459-470.
 70. Ashbeck EL, Jacobs ET, Martinez ME, Gerner EW, **Lance P**, Thompson PA. Components of metabolic syndrome and metachronous colorectal neoplasia. *Cancer Epidemiol Biomarkers Prev* 2009; 18(4):1134-1143. PMC2737414
 71. Benuzillo JG, Jacobs ET, Hoffman RM, Heigh RI, **Lance P**, Martinez ME. Rural-urban differences in colorectal cancer screening capacity in Arizona. *J Community Health* 2009; 34(6): 523-528.
 72. Thompson PA, Wertheim BC, Roe DJ, Ashbeck EL, Jacobs ET, **Lance P**, Martinez ME, Alberts DS. Gender modifies the effect of ursodeoxycholic acid (UDCA) treatment for the prevention of colorectal adenomas. *Cancer Prev Res (Phila)* 2009; 2(12):1023-1030.
 73. Bartley AN, Thompson PA, Buckmeier JA, Kepler CY, Hsu CH, Snyder MS, **Lance P**, Bhattacharyya A, Hamilton SR. Expression of gastric polyp mucin, MUC6, in colorectal serrated polyps. *Mod Pathol* 2010; 23(2):169-176. Epub 2009 Oct 23. PMC2818151
 74. Friedman AC, **Lance P**. Re: "CMS's landmark decision on CT colonography": misguided and short-sighted: pay me now or pay me later. *J Am Coll Radiol* 2010; 7(2):159-160.
 75. Friedman AC, Downing D, Chino J, Krupinski E, Kilian C, **Lance P**. Feasibility of remote CT colonography at two rural Native American medical centers. *AJR Am J Roentgenol* 2010; 195(5):1110-1117.
 76. Brevik A, Joshi AD, Corral R, Onland-Moret NC, Siegmund KD, Le Marchand L, Baron JA, Martinez ME, Haile RW, Ahnen DJ, Sandler RS, **Lance P**, Stern MC. Polymorphisms in base excision repair genes as colorectal cancer risk factors and modifiers of the effect of diets high in red meat. *Cancer Epidemiol Biomarkers Prev* 2010; 19(12):3167-3173. PMC3058341
 77. Leroy EC, Moore JH, Hu C, Martinez ME, **Lance P**, Duggan D, Thompson PA. Genes in the insulin and insulin-like growth factor pathway and odds of metachronous colorectal neoplasia. *Hum Genet* 2011; 129(5):503-512.
 78. Hsu CH, Li Y, Long Q, Zhao Q, **Lance P**. Estimation of recurrence of colorectal adenomas with dependent censoring using weighted logistic regression. *PLoS One* 2011; 6(10):e25141. PMC3204965
 79. **Lance P**, Thompson PA. Chemoprevention of colorectal neoplasia: Translating scientific promise into clinical practice. *J Carcinog.* 2011;10:11. PMC3122103
 80. Jacobs E, Martinez ME, Buckmeier J, **Lance P**, May M, Jurutka P. Circulating fibroblast growth factor-23 is associated with increased risk for metachromous colorectal adenoma. *J Carcinog.* 2011 Feb 12;10:3. PMC3049272
 81. Wang J, Joshi AD, Corral R, Siegmund KD, Marchand LL, Martinez ME, Haile RW, Ahnen DJ, Sandler RS, **Lance P**, Stern MC. Carcinogen metabolism genes, red meat and poultry intake, and colorectal cancer risk. *Int J Cancer* 2012; 130(8):1898-1907.
 82. Wertheim BC, Smith JW, Fang C., Alberts DS, **Lance P**, and Thompson P. Risk modification of colorectal adenoma by CYP7A1 polymorphisms and the role of bile acid metabolism in carcinogenesis. *Cancer Prev Res (Phila).* 2012; 5(2):197-204. PMC3400261
 83. Zhu Y, Zhu M, and **Lance P**. iNOS signaling interacts with COX-2 pathway in colonic fibroblasts. *Exp Cell Res.* 2012; 318(16):2116-2127.
 84. Zhu Y, Zhu M, and **Lance P**. IL1 β -mediated stromal COX-2 signaling mediates proliferation and invasiveness of colonic epithelial cancer cells. *Exp Cell Res.* 2012; 318(19):2520-2530.

85. Zhu Y, Zhu M, and **Lance P**. Stromal COX-2 signaling activated by deoxycholic acid mediates proliferation and invasiveness of colorectal epithelial cancer cells. *Biochem Biophys Res Commun*. 2012; 425(3):607-612.
86. Thompson P, Roe D, Fales L, Buckmeier J, Wang F, Hamilton S, Bhattacharyya A, Green S, Hsu CC, Chow HS, Ahnen D, Boland CR, Heigh R, Fay D, Martinez M, Jacobs E, Ashbeck E, Alberts, DS, and **Lance P**. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. *Cancer Prev Res (Phila)*. 2012; 5(12):1381-1393. PMC3518663
87. Coxib and traditional NSAID Trialists' (CNT) Collaboration (**Lance P**, member). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analysis of individual participant data from randomized trials. *Lancet*, Published online May 30, 2013.

II. Selected Books, Chapters and Reviews

1. Wastell C, Lance P, eds. *Cimetidine. The Westminster Hospital Symposium 1978*. Edinburgh: Churchill Livingstone, 1978.
2. Lance P, Filipe MI, Wastell C. Non-ulcer dyspepsia, duodenitis and cimetidine. In: Wastell C, Lance P (eds). *Cimetidine: The Westminster Hospital Symposium 1978*. Edinburgh: Churchill Livingstone, 1978.
3. Zeegen R, Lance P. Oesophagus, stomach, and small intestine. In: Bodley Scott R, Fraser R (eds). *Medical Annual 1979/80*. Bristol: John Wright, 1980.
4. Zeegen R, Lance P. Oesophagus, stomach, and large intestine. In: Bodley Scott R, Fraser R (eds). *Medical Annual 1980/81*. Bristol: John Wright, 1981.
5. Zeegen R, Lance P. Oesophagus, stomach, small and large intestine. In: Bodley Scott R, Fraser R (eds). *Medical Annual 1981/82*. Bristol: John Wright, 1982.
6. Lance P, Gazzard BG. Spastic colon. *Postgraduate Doctor Middle East* 1981, 478-484.
7. Gazzard BG, Lance P. Diseases of the Digestive System. In: Miller DL, Farmer RDT (eds). *Epidemiology of Diseases*. Oxford: Blackwell Scientific, 1982.
8. Lance P, Boland CR, Kim YS. Glycoconjugates of the small intestine and colon. In: Glass GBJ, Sherlock P (eds). *Progress in Gastroenterology*. 4th ed. New York: Grune and Stratton, 1983, 31-56.
9. Gazzard BG, Lance P. Inflammatory bowel disease and pregnancy. In: Baldwin RWM, Hanson CG (eds). *The Critically Ill Obstetric Patient*. London: Farrand Press, 1984, 416-426.
10. Gazzard BG, Lance P. Hepatic failure in pregnancy. In: Baldwin RWM, Hanson GC (eds). *The Critically Ill Obstetric Patient*. London: Farrand Press, 1984, 339-415.
11. Lance P. Selected Summary: Tissue-specific modification of a mature mRNA. *Gastroenterology* 1989; 96:1215-1216.
12. Lance P. Selected Summary: Colonoscopy - who can avoid it? *Gastroenterology* 1989; 6:1613-1614.
13. Lance P. Colorectal cancer - to screen or not to screen. *HMO Practice* 1989; 6:137-141.
14. Lance P. Contributor in: Lev R. *Adenomatous Polyps of the Colon*. New York: Springer-Verlag, 1990.
15. Lance P. Selected Summary: CEA as a cell adhesion molecule. *Gastroenterology* 1990; 99:277-8.
16. Lance P. Selected Summary: Sialylation and metastatic colon cancer. *Gastroenterology* 1990; 99:564-5.
17. Lance P. Tumors and other neoplastic diseases of the small bowel. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE (eds). *Textbook of Gastroenterology*. 1st ed. Philadelphia: JB Lippincott Company, 1991, 1485-1503.
18. Lance P. Tumors and other neoplastic diseases of the small bowel. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE (eds). *Atlas of Gastroenterology*. 1st ed. Philadelphia: JB Lippincott Company, 1992, 208-214.
19. Lance P, Grossman S, Marshall JR. Screening for colorectal cancer. *Semin Gastrointest Dis* 1992; 3:22-32.
20. Lance P. Tumors and other neoplastic diseases of the small bowel. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE (eds). *Textbook of Gastroenterology*. 2nd ed. Philadelphia: JB Lippincott Company, 1995, 1696-1714.
21. Kim EC, Lance P. Colorectal polyps and their relationship to cancer. *Gastroenterol Clin North Am* 1997; 26:1-17.

22. Burkard PG, Connolly BA, Lance P. Clinical decision making in colorectal cancer screening. *J Clin Outcomes Management* 1997; 4:45-53.
23. Lance P. Recent developments in colorectal cancer. *J R Coll Physicians Lond* 1997;31:483-487.
24. Gruber M, Lance P. Colorectal cancer detection and screening. *Lippincott's Primary Care Practice* 1998;4:369-376.
25. Lance P. Tumors and other neoplastic diseases of the small bowel. In: Yamada T, Alpers DH, Laine L, Owyang C, Powell DW (eds). *Textbook of Gastroenterology*. 3rd ed. Philadelphia: JB Lippincott Company, 1999, 1722-1738.
26. Lance P. Tumors and other neoplastic diseases of the small bowel. In: Yamada T, Alpers DH, Laine L, Owyang C, Powell DW (eds). *Atlas of Gastroenterology*. 2nd ed. Philadelphia: JB Lippincott Company, 1999, 305-311.
27. Burkard PG, Lance P. MALT and other GI lymphomas. *Curr Opin Gastroenterol*, 2000;16:107-112.
28. Ismail A, Gerner E, Lance P. Colorectal Cancer Prevention. In Alberts D, Hess L (eds). *Fundamentals of Cancer Prevention*. 2nd ed. Heidelberg: Springer, 2009, 203-222.
29. Lance P, Thompson P. Colorectal Cancer Prevention. In Alberts D, Hess L (eds). *Fundamentals of Cancer Prevention*. 3rd ed. Heidelberg: Springer 2013, in press